Pharmaceutical product, medical food or dietary supplement for preventing cancer and inflammatory diseases
AssigneePhytogen Medical Foods S.L.
InventorsCarlos María Peña Díaz, Guillerm Muñoz Fernández, Michael Morse
Life of this patent
Estimating the term…
Abstract
The present invention relates to cancer therapy by administering a specific dietary composition. Especially the invention relates to a pharmaceutical, medical food or dietary supplement composition comprising the combination of the following three active ingredients: hydroxytyrosol, fish oil EPA/DHA and curcumin. The pharmaceutical composition is useful in the treatment or prevention of cancer, especially breast cancer.
Claims21
A composition comprising:
- a. Hydroxytyrosol and/or a hydroxytyrosol analogues,
- b. curcumin and/or a curcumin analogues, and
- c. Omega-3 polyunsaturated fatty acids (PUFAs) EPA and DHA, in a weight ratio of EPA:DHA of from 1.2 to 1.8.
A method of reducing the levels of CRP in plasma of a subject diagnosed with breast cancer, the method comprising orally administering to said subject a composition comprising:
- a. Hydroxytyrosol and/or a hydroxytyrosol analogues,
- b. curcumin and/or a curcumin analogues, and
- c. Omega-3 polyunsaturated fatty acids (PUFAs) EPA and DHA, in a weight ratio of EPA:DHA of from 1.2 to 1.8;
- such that said levels of CRP in the plasma are reduced.
A method of increasing the overall survival rate of a subject diagnosed with breast cancer, the method comprising orally administering to said subject a composition comprising:
- a. Hydroxytyrosol and/or a hydroxytyrosol analogues;
- b. curcumin and/or a curcumin analogues;
- and
- c. Omega-3 polyunsaturated fatty acids (PUFAs) EPA and DHA, in a weight ratio of EPA:DHA of from 1.2 to 1.8;
- such that said overall survival rate is increased.
A method of reducing inflammation in a subject diagnosed with breast cancer, the method comprising orally administering to said subject a composition comprising:
- a. Hydroxytyrosol and/or a hydroxytyrosol analogues;
- b. curcumin and/or a curcumin analogues;
- and
- c. Omega-3 polyunsaturated fatty acids (PUFAs) EPA and DHA, in a weight ratio of EPA:DHA of from 1.2 to 1.8;
- such that said inflammation is reduced.
Dependencies are inferred from the claim text.